Update on triple-negative breast cancer: Prognosis and management strategies

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 511-520

  Brouckaert, Olivier ^a   Wildiers, Hans ^a   Floris, Giuseppe ^a   Neven, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Review; Triple negative

Indexed keywords

ANDROGEN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERIBULIN; ESTROGEN RECEPTOR; EVEROLIMUS; GEMCITABINE; HISTONE DEACETYLASE; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; UNINDEXED DRUG; VASCULOTROPIN; VELIPARIB;

AGE DISTRIBUTION; BREAST FEEDING; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DNA CROSS LINKING; DRUG DNA BINDING; EPIDERMAL GROWTH FACTOR RECEPTOR 1 GENE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; RACE DIFFERENCE; RECEPTOR GENE; REVIEW; TRIPLE NEGATIVE BREAST CANCER; WAIST HIP RATIO;

EID: 84866990604     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Surveillance Epidemiology and End Results (SEER). Lifetime risk of developing or dying of cancer [webpage on the Internet]. Bethesda, MD: Surveillance Research Program; nd. Available from: http://seer.cancer.gov/statistics/types/lifetimerisk.html. Accessed May 15, 2012.
3. Perou CM, Sorlie T, Eisen MB, etal. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
4. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel Members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-1747.
5. Layfield LJ, Gupta D, Mooney EE. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methods. Breast J. 2000;6(3):189-196.
6. Putti TC, Pinder SE, Elston CW, Lee AH, Ellis IO. Breast pathology practice: most common problems in a consultation service. Histopathology. 2005;47(5):445-457.
7. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23(30):7512-7517.
8. Regitnig P, Reiner A, Dinges HP, etal. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch. 2002;441(4): 328-334.
9. Eiermann W, Paepke S, Appfelstaedt J, etal; Letrozole Neo-Adjuvant Breast Cancer Study Group. Letrozole neo-adjuvant breast cancer study group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527-1532.
10. Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006;12(15):4614-4618.
11. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4): 195-197.
12. McCullough AE, Dell'Orto P, Reinholz MM, etal. Concordance of HER2 central assessment by two international central laboratories: a ring study within the framework of the adjuvant HER2-positive ALTTO trial (BIG2-06/N063D/EGF106708). Cancer Res. 2010;70(Suppl):abst P3-10-36.
13. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2in breast cancer. Mod Pathol. 2010;23 Suppl 2:S52-S59.
14. Nagle RB, Böcker W, Davis JR, etal. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem. 1986;34(7):869-881.
15. Dairkee SH, Puett L, Hackett AJ. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst. 1988;80(9):691-695.
16. Pintens S, Neven P, Drijkoningen M, etal. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J Clin Pathol. 2009;62(7):624-628.
17. Ciocca DR, Gago FE, Fanelli MA, Calderwood SK. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications. J Steroid Biochem Mol Biol. 2006;102(1-5):32-40.
18. Carey LA, Perou CM, Livasy CA, etal. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21): 2492-2502.
19. Nielsen TO, Hsu FD, Jensen K, etal. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
20. Cuzick J, Dowsett M, Wale C, etal. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score-results from TransATAC. Cancer Res. 2009;69 Suppl 24:abst 74.
21. Rakha EA, Elsheikh SE, Aleskandarany MA, etal. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009;15:2302-2310.
22. Kreike B, van Kouwenhove M, Horlings H, etal. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
23. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple negative breast cancer. Cancer. 2007;109:25-32.
24. Cheang MC, Voduc D, Bajdik C, etal. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
25. Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol. 2008;97:30-34.
26. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol. 2006;19:1506-1511.
27. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2010;15 Suppl 5:39-48.
28. Parker JS, Mullins M, Cheang MC, etal. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160-1167.
29. Bertucci F, Finetti P, Cervera N, etal. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236-240.
30. de Ronde JJ, Hannemann J, Halfwerk H, etal. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat. 2010;119:119-126.
31. Lehman BD, Bauer JA, Chen X, etal. Transcriptome analysis of triple negative breast cancers identifies six distinct biological subgroups and reveals therapeutic strategies. Cancer Res. 2010;70:24s Suppl:abst PD01-07.
32. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721-1728.
33. Morris GJ, Naidu S, Topham AK, etal. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007;110:876-884.
34. Stead LA, Lash TL, Sobieraj JE, etal. Triple negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11(2):R18.
35. Lund MJ, Trivers KF, Porter PL, etal. Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113:357-370.
36. Millikan RC, Newman B, Tse CK, etal. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139.
37. Foulkes WD, Stefansson IM, Chappuis PO, etal. Germline BRCA1mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485.
38. Evans DG, Howell A. Are we ready for online tools in decision making for BRCA1/2mutation carriers? J Clin Oncol. 2012;30(5): 471-473.
39. Antoniou AC, Beesley J, McGuffog L, etal; CIMBA. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2mutation carriers: Implications for risk prediction. Cancer Res. 2010;70:9742-9754.
40. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568-2581.
41. Reis-Filho JS, Tutt AJ. Triple negative tumours: a critical review. Histopathology. 2008;52:108-118.
42. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology. 2002;34(4):309-314.
43. Fulford LG, Easton DF, Reis-Filho JS, etal. Specific morphological features predictive for the basal phenotype in grade 3invasive ductal carcinoma of the breast. Histopathology. 2006;49:22-34.
44. Young S, Pilarski R, Donenburg T, etal. The prevalence of BRCA mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.
45. Kwon JS, Gutierrez-Barrera AM, Young D, etal. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010;28:4214-4220.
46. Futreal PA, Liu Q, Shattuck-Eidens D, etal. BRCA1mutations in primary breast and ovarian carcinomas. Science. 1994;266:120-122.
47. Lancaster JM, Cochran CJ, Brownlee HA, etal. Detection of BRCA1mutations in women with early-onset ovarian cancer by use of the protein truncation test. J Natl Cancer Inst. 1996;88:552-554.
48. Esteller M, Sparks A, Toyota M, etal. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000;60:4366-4371.
49. Baldwin RL, Nemeth E, Tran H, etal. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000;60:5329-5333.
50. Grushko TA, Nwachukwu N, Charoenthammaraksa S, etal. Evaluation of BRCA1inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. J Clin Oncol. 2010;28(Suppl):abst 10510.
51. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4:814-819.
52. Turner NC, Reis-Filho JS, Russell AM, etal. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;14:2126-2132.
53. Phipps A, Malone K, Porter P, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, Her-2-overexpressing, and triple-negative breast cancer. Cancer. 2008;113:1521-1526.
54. Yang X, Sherman M, Rimm D, etal. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 2007;16:439-443.
55. Dent R, Trudeau M, Pritchard KI, etal. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13: 4429-4434.
56. Collett K, Stefansson IM, Eide J, etal. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev. 2005;14:1108-1112.
57. Yang WT, Dryden M, Broglio K, etal. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008;111:405-410.
58. Wang Y, Ikeda DM, Narasimhan B, etal. Estrogen receptor negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology. 2008;246:367-375.
59. Kim SH, Seo BK, Lee J, etal. Correlation of ultrasound findings with histology, tumor grade, and biological markers in breast cancer. Acta Oncol. 2008;47:1531-1538.
60. Basu S, Chen W, Tchou J, etal. Comparison of triple negative and estrogen receptor-positive/progesterone receptorpositive/ HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995-1000.
61. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23: 123-133.
62. Tognon C, Knezevich SR, Huntsman D, etal. Expression of the ETV6-NTRK3gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367-376.
63. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009;106(44):18740-18744.
64. Azoulay S, Laé M, Fréneaux P, etal. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 2005;18:1623-1631.
65. Fourquet A, Vilcoq JR, Zafrani B, Schlienger P, Jullien D, Campana F. Medullary breast carcinoma: the role of radiotherapy as primary treatment. Radiother Oncol. 1987;10:1-6.
66. Dendale R, Vincent-Salomon A, Mouret-Fourme E, etal. Medullary breast carcinoma: prognostic implications of p53 expression. Int J Biol Markers. 2003;18:99-105.
67. Huober JB, Gelber S, Thurlimann B, etal. Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials. J Clin Oncol. 2010;28 Suppl:abst 630.
68. Hennessy BT, Giordano S, Broglio K, etal. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17:605-613.
69. Piccart M, Viale G, Ellis P, Abramowicz M, Carey L. Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice? Ecancermedicalscience. 2011;5:217.
70. Kusinska R, Potemski P, Jesionek-Kupnicka D, Kordek R. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma relation with grade, stage, estrogen receptor and HER2. Pol J Pathol. 2005;56:107-110.
71. Crabb SJ, Cheang MC, Leung S, etal. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008;8:249-256.
72. Tan DS, Marchió C, Jones RL, etal. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111:27-44.
73. Foulkes WD, Metcalfe K, Hanna W, etal. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA-1 related breast carcinoma. Cancer. 2003;98:1569-1577.
74. Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29(17):2301-2304.
75. Kennecke H, Yerushalmi R, Woods R, etal. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271-3277.
76. Freedman G, Anderson P, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009;115:946-951.
77. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684-1691.
78. Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831-841.
79. Montagna E, Bagnardi V, Rotmensz N, etal. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol. 2012;23(2):324-331.
80. Liedtke C, Mazouni C, Hess KR, etal. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275-1281.
81. Smid M, Wang Y, Zhang Y, etal. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108-3114.
82. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608-3617.
83. Heitz F, Harter P, Traut A, etal. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. J Clin Oncol. 2008;26; Suppl:abst 1010.
84. Dawood S, Broglio K, Esteva FJ, etal. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009;20:621-627.
85. Desmedt C, Haibe-Kains B, Wirapati P, etal. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14:5158-5165.
86. Keam B, Im SA, Lee KH, etal. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13(2):R22.
87. Aleskandarany MA, Green AR, Benhasouna AA, etal. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 2012;14(1):R3.
88. Cancello G, Maisonneuve P, Rotmensz N, etal. Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat. 2011;127(3):713-720.
89. Albergaria A, Ricardo S, Milanezi F, etal. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer. 2011;11:299.
90. Tang D, Xu S, Zhang Q, Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol. 2012;29(2):526-533.
91. Kashiwagi S, Yashiro M, Takashima T, etal. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer. 2010;103(2): 249-255.
92. Viale G, Rotmensz N, Maisonneuve P, etal. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009; 116(2):317-328.
93. Mohammed RA, Ellis IO, Mahmmod AM, etal. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol. 2011;24(6):774-785.
94. Prat A, Parker JS, Karginova O, etal. Phenotypic and molecular characterization of the claudinlow intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.
95. Ono M, Tsuda H, Shimizu C, etal. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132(3): 793-805.
96. Desmedt C, Di Leo A, de Azambuja E, etal. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011;29: 1578-1586.
97. von Minckwitz G, Untch M, Blohmer JU, etal. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-1804.
98. Rouzier R, Perou CM, Symmans WF, etal. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-5685.
99. Carey LA, Dees EC, Sawyer L, etal. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
100. Straver ME, Glas AM, Hannemann J, etal. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010;119(3):551-558.
101. Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(15):1747-1749.
102. Metzger-Filho O, Tutt A, de Azambuja E, etal. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012;30(15): 1879-1887.
103. Di Leo A, Desmedt C, Bartlett JM, etal. Final results of a meta-analysis testing HER2 and topoisomerase IIal pha genes as predictors of incremental benefit from anthracyclines in breast cancer. J Clin Oncol. 2010;28:72s Suppl:abst 519.
104. Rocca A, Paradiso A, Sismondi P, etal. Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. J Clin Oncol. 2011;29:87s Suppl:abst 1031.
105. De Laurentiis M, Cancello G, D'Agostino D, etal. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol. 2008;26(1): 44-53.
106. Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Peto R, Davies C, Godwin J, etal. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-444.
107. Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16:53-61.
108. Gronwald J, Byrski T, Huzarski T, etal. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol. 2009;27:7s Suppl:abst 502.
109. Byrski T, Huzarski T, Dent R, etal. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115:359-363.
110. Byrski T, Gronwal dJ, Huzarski T, etal. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010;28: 375-379.
111. Alba E, Chacon J, Lluch A, etal. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-2003-A multicenter, randomized phase II study. J Clin Oncol. 2011;29:83s Suppl:abst 1015.
112. Amir E, Miller N, Geddie W, etal. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30(6):587-592.
113. Forastiere AA, Hakes TB, Wittes JT, Wittes RE. Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol. 1982;5(3): 243-247.
114. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol. 1988;6(12): 1811-1814.
115. O'Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol. 1993;11(11):2112-2117.
116. Albain KS, Nag SM, Calderillo-Ruiz G, etal. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthra ycline treatment. J Clin Oncol. 2008;26(24): 3950-3957.
117. O'Shaughnessy J, Miles D, Vukelja S, etal. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-2823.
118. Thomas ES, Gomez HL, Li RK, etal. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-5217.
119. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat. 2010;121(2):261-271.
120. Miller K, Wang M, Gralow J, etal. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666-2676.
121. Miles DW, Chan A, Dirix LY, etal. Phase III study of bevacizumab plus docetaxel compared with plac ebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239-3247.
122. O'Shaughnessy JA, Brufsky AM. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2008;8:370-373.
123. FDA pulls approval for avastin in breast cancer. Cancer Discov. 2011;1(7):OF1-OF2. Epub November 23, 2011.
124. Ryan PD, Tung NM, Isakoff M, etal. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol. 2009;27:15s Suppl:abst 551.
125. Gerber B, Eidtmann H, Rezai M, etal. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol. 2011;29:81s:abst 1006.
126. Bear HD, Tang G, Rastogi P, etal. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol. 2011;29:abst LBA 1005.
127. Hoffmann-La Roche. BEATRICE Study: a study of avastin (bevacizumab) adjuvant therapy in triple negative breast cancer. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated August 15, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT00528567. Accessed May 15, 2012.
128. Hashimoto K, Tamura K. Breakthrough breast cancer treatment-Parp inhibitor, BRCA, and triple negative breast cancer. Gan To Kagaku Ryoho. 2010;37:1187-1191. [Japanese].
129. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res. 2007;13: 1383-1388.
130. Fong PC, Boss DS, Yap TA, etal. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.
131. Isakoff SJ, Overmoyer B, Tung NM, etal. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol. 2010;28:abst 1019.
132. Tutt A, Robson M, Garber JE, etal. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-244.
133. Gelmon KA, Tischkowitz M, Mackay H, etal. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852-861.
134. O'Shaughnessy J, Schwartzberg LS, Danso MA, etal. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29:abst 1007.
135. Dent RA, Lindeman GJ, Clemons M, etal. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first-or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol. 2010;28:abst 1018.
136. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol. 2012. [Epub ahead of print.]
137. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 2002;71:67-75.
138. Baselga J, Stemmer S, Pego A, etal. Cetuximab+ cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res. 2010;70:abst PD01-01.
139. O'Shaughnessy J, Weckstein D, Vukelja S, etal. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat. 2007;106:S32:abst 308.
140. Carey LA, Rugo HS, Marcom PK, etal. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol. 2008;26:abst 1009.
141. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8): 671-688.
142. Hochgräfe F, Zhang L, O'Toole SA, etal. Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells. Cancer Res. 2010;70:9391-9401.
143. Finn RS, Dering J, Ginther C, etal. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105(3):319-326.
144. Lacevic M, Minton S, Schmitt M, etal. Phase II trial of the HDAC inhibitor, vorinostat, in combination with tamoxifen for patients with advanced breast cancer who have failed prior antihormonal therapy. Breast Cancer Res Treat. 2007;106 Suppl 1:abst 2097.